此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

采用抗 PD-1 疗法和放化疗组成的非手术方法治疗肌层浸润性膀胱癌 (BCIRT-01)

2026年11月7日 更新者:Yuan-hong Gao、Sun Yat-sen University

一项单臂 II 期临床试验,采用诱导化疗加抗 PD-1 治疗,随后放疗加同步抗 PD-1 治疗来治疗肌层浸润性膀胱癌

The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment mode which consists of neoadjuvant chemotherapy plus anti-programmed cell death protein 1 (anti-PD-1) therapy followed by radiotherapy plus concurrent anti-PD-1 therapy. The main questions it aims to answer are: (i) whether the anti-PD-1 antibody, toripalimab, is effective in treating muscle-invasive bladder cancer (MIBC), when combined with chemoradiation; (ii) whether toripalimab is safe in combination with chemoradiation. Participants will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy plus 2 cycles of concurrent toripalimab.

研究概览

详细说明

Bladder cancer is the second most common malignancies over the world. At initial diagnosis, the cases with muscle-invasive bladder cancer (MIBC) accounts nearly 20% of all bladder cancer patients. And 40% of non-muscle-invasive bladder cancer could develop to MIBC. Currently, radical cystectomy (RC) is the golden standard to manage MIBC. Yet, it brings severe surgical injuries and post-surgical complications which impair life quality of the patients. Recently, bladder-preserving treatment based gradually becomes the second choice for MIBC. It consists of maximal transurethral resection of bladder tumor (TURBT) and chemoradiation. A series of clinical trials and meta-analyses supported that the bladder-preserving treatment has a similar therapeutic effect compared with RC. But it is noteworthy that this treatment mode does not really avoid surgery. TURBT could also cause complications, such as haemorrhage, infection, perforation, and even tumor dissemination. Moreover, the incidence of serious toxicities brought by concurrent chemoradiation is as high as 36%. In actual clinical work, it is hard for more than half patients to complete chemoradiation of standard intensity. Additionally, many patients are unsuitable for bladder preservation, including those with T stage > T2, diameter > 5 cm, hydronephrosis and positive lymph nodes. Hence, it calls for improvement of current bladder preservation mode, to make more MIBC patients receive radical treatment which brings better therapeutic experience and life quality.

Many lab studies indicated that formation and progression of bladder cancer is a process of mutation accumulation. It provides biological fundamentals for immune checkpoint inhibitors, such as anti-programmed cell death protein 1 (anti-PD-1) antibodies. Based on available clinical studies, anti-PD-1 antibodies exhibits ideal therapeutic effects in bladder cancer of different stages and has an incidence of toxicities as low as 13%. Its toxicities mainly include arthralgia and hyponatremia, which are well tolerated. Currently, there are more than 10 clinical trials trying anti-PD-1 antibodies for bladder preservation. However, the treatment modes in most of them still contain TURBT. This phase 2 trial intended to evaluate the therapeutic and adverse effects of a non-surgical bladder-preserving treatment mode consisting of anti-PD-1 antibodies and chemoradiation, in a small patient cohort with MIBC. The results might provide an effective, non-invasive and low-toxic choice which improves patient experience and realizes bladder preservation.

研究类型

介入性

注册 (估计的)

64

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • Cancer Center, Sun Yat-sen University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Pathologically diagnosed bladder malignant tumor via biopsy
  • Urothelial carcinoma as the primary histological component
  • Pretreatment clinical TNM stage as T2-4aN0-2M0 (UICC TNM staging classification, version 8)
  • Age between 18 and 75 years old
  • Karnofsky performance score ≥ 70
  • Creatinine clearance rate ≥ 30 ml/min

Exclusion Criteria:

  • Simultaneous tumors of the urethra or upper urinary tract
  • Existence of small cell cancer component
  • Uncontrolled tuberculosis, viral hepatitis or AIDS
  • Autoimmune or mental diseases
  • Severe cardiac, renal, hepatic or hematopoietic dysfunctions unsuitable for chemotherapy, radiotherapy or immune checkpoint inhibiting therapy
  • Prior history of other malignancies within 5 years, except cured cervical carcinoma in situ and skin basal cell carcinoma
  • Prior history of pelvic radiotherapy or chemotherapy
  • Poor adherence to regular follow-up (cystoscopy, CT, MRI, etc.)
  • Pregnant or lactating women
  • Treatment with glucocorticoid or immunosuppressive drugs within 1 month
  • Other situations for which the investigators consider a patient inappropriate to participate

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Toripalimab plus chemoradiation

This study has only single arm in which the patients will receive neoadjuvant chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy

The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.

Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the neoadjuvant and concurrent phases, respectively.

其他名称:
  • JS001

The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.

Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles.

The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.

Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.

The patients in this arm will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.

Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions.

The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.

Carbopatin: Used when creatinine clearance rate 30-39 ml/min, area under curve 4 on Day 1, repeated every 3 weeks, totally 3 cycles.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinical complete response (cCR) rate
大体时间:When the eligible patients complete the treatment and followed-up for half a year

The percentage of the cases attaining cCR of primary tumor and regional lymph nodes (confirmed by radiologic examinations, such as thoraco-bdominal computed tomography, pelvic magnetic resonance imaging, and multipoint biopsy under cystoscopy)

When the eligible patients complete the treatment and followed-up for half a year

次要结果测量

结果测量
措施说明
大体时间
Overall survival (OS)
大体时间:When the eligible patients complete the treatment and followed-up for 1 and 2 years

The percentage of the cases surviving over a given time period

When the eligible patients complete the treatment and followed-up for 1 and 2 years
Bladder-intact event-free survival (BI-EFS)
大体时间:When the eligible patients complete the treatment and followed-up for 1 and 2 years

The percentage of the cases surviving with intact bladder and without muscle-invasive recurrence, regional lymph node recurrence or distant metastasis, over a given time period

When the eligible patients complete the treatment and followed-up for 1 and 2 years
Disease-free survival (DFS)
大体时间:When the eligible patients complete the treatment and followed-up for 1 and 2 years

The percentage of the cases surviving without locoregional recurrence or distant metastasis over a given time period

When the eligible patients complete the treatment and followed-up for 1 and 2 years
Local recurrence (LR) rate
大体时间:When the eligible patients complete the treatment and followed-up for 1 and 2 years

The percentage of the cases with locoregional recurrence over a given time period

When the eligible patients complete the treatment and followed-up for 1 and 2 years
Incidence of grade 3/4 (G3/4) toxicities
大体时间:Once a week during treatment, and once per 3 months after treatment, until the last follow-up (2 years after treatment)

The percentage of the cases with any G3/4 toxicity during and after treatment

Once a week during treatment, and once per 3 months after treatment, until the last follow-up (2 years after treatment)
Bladder function
大体时间:Once per 3 months after treatment, until the last follow-up (2 years after treatment)

The quantitative score of bladder function at a given time point, based on the Quality of Life 30-item Questionnaire, Bladder Module (QLQ-BLM30) from the EORTC

Once per 3 months after treatment, until the last follow-up (2 years after treatment)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yuanhong Gao, MD、Sun Yat-sen University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年12月1日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2023年7月27日

首先提交符合 QC 标准的

2023年7月27日

首次发布 (实际的)

2023年8月3日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月7日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅